Here's What Key Metrics Tell Us About ResMed (RMD) Q4 Earnings

ResMed (RMD) reported robust Q4 2025 results, with revenue of $1.35 billion, a 10.2% year-over-year increase, and EPS of $2.55, significantly exceeding Zacks consensus estimates by 1.87% and 3.66% respectively. The company demonstrated strong performance across key operational metrics, including devices, masks, and residential care software, with most segments meeting or surpassing analyst projections and showing healthy year-over-year growth. This strong financial showing contributed to RMD shares outperforming the S&P 500, gaining 8.4% over the past month, though the stock currently holds a Zacks Rank #3 (Hold).

Analysis

ResMed (RMD) delivered a robust fourth-quarter performance for fiscal 2025, exceeding analyst expectations on both revenue and earnings. The company reported revenue of $1.35 billion, a 10.2% year-over-year increase that surpassed the Zacks Consensus Estimate by 1.87%. Earnings per share came in at $2.55, representing a significant 22.6% increase from the prior year's $2.08 and beating consensus forecasts by 3.66%. A detailed look at the key metrics reveals broad-based strength, particularly in international markets, where revenue grew 13.1% YoY, and in the high-margin global "Masks and other" category, which saw an 11.7% YoY increase. While nearly all segments met or exceeded projections, the U.S., Canada, and Latin America devices segment posted revenue of $432.8 million, a slight miss against the $435.08 million analyst estimate, even while growing 6.6% YoY. This strong overall report has been reflected in the stock's recent performance, which has returned +8.4% over the past month, significantly outpacing the S&P 500 composite. Despite these positive results, the stock currently holds a Zacks Rank #3 (Hold), suggesting that the market may view the company as fairly valued after its recent run-up.

Key Decisions for Investors

• Given the strong top- and bottom-line beats and double-digit growth across most key segments, these results affirm the company's solid fundamental picture and may justify holding or adding to existing long positions.
• Investors should monitor the U.S., Canada, and Latin America devices segment in subsequent quarters, as its slight miss on revenue estimates was the only point of relative weakness and could indicate emerging regional challenges.
• Considering the stock's recent 8.4% outperformance and its neutral 'Hold' rating from Zacks, new capital should be deployed cautiously, as the positive earnings news may already be largely priced into the current share value.